In the last 10 years, the wide application of PDX (Patient-Derived Xenograft) has advanced preclinical evaluations and can forecast the clinical efficacy of tumor drugs. The pharmacodynamic effect of large-scale PDX models on anti-cancer drugs reflects the clinical application result in the patient populations. Therefore, researching the preclinical pharmacodynamic effects of new anti-cancer drugs by using PDX models is helpful for the deeper evaluation and potential clinical applications of new drugs.
The severely immuno-deficient B- NDG mice are more suitable than other immuno-deficient mice for PDX model establishment
The tumor model retains the high heterogeneity of tumor tissue, and partial medium compositions of tumor microenvironment are preserved
It overcomes the high homology problem of traditional models using tumor cell line cells, and more closely resembles the patient's tumor tissue
The PDX model library can provide a more in-depth assessment and potential preclinical applications of new drugs
It can be used in the preclinical evaluation and forecast clinical efficacy of tumor drugs
It is suitable to study the mechanism of tumorigenesis
PDX model successfully built on the B-NDG mouse (example)
B-NDG mice show significant PDX model advantages compared to scid mice
Fig. 1 (A) The gastric sample from a patient was inoculated and formed a subcutaneous tumor on a B-NDG mouse. (B) The tumor growth curve of the patient’s gastric sample in B-NDG mice. (C) Comparing a patient’s gastric sample tumor formation rate between CB17-scid and B-NDG mice.